146 related articles for article (PubMed ID: 17909358)
1. Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
Krug LM; Milton DT; Jungbluth AA; Chen LC; Quaia E; Pandit-Taskar N; Nagel A; Jones J; Kris MG; Finn R; Smith-Jones P; Scott AM; Old L; Divgi C
J Thorac Oncol; 2007 Oct; 2(10):947-52. PubMed ID: 17909358
[TBL] [Abstract][Full Text] [Related]
2. The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by (111)Indium-labeled humanized monoclonal antibody 3S193.
Quaia E; Krug LM; Pandit-Taskar N; Nagel A; Reuter VE; Humm J; Divgi C
Eur J Radiol; 2008 Aug; 67(2):292-299. PubMed ID: 17714905
[TBL] [Abstract][Full Text] [Related]
3. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
[TBL] [Abstract][Full Text] [Related]
4. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
5. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Cancer Res; 2000 Sep; 60(17):4804-11. PubMed ID: 10987290
[TBL] [Abstract][Full Text] [Related]
6. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.
Scott AM; Tebbutt N; Lee FT; Cavicchiolo T; Liu Z; Gill S; Poon AM; Hopkins W; Smyth FE; Murone C; MacGregor D; Papenfuss AT; Chappell B; Saunder TH; Brechbiel MW; Davis ID; Murphy R; Chong G; Hoffman EW; Old LJ
Clin Cancer Res; 2007 Jun; 13(11):3286-92. PubMed ID: 17545534
[TBL] [Abstract][Full Text] [Related]
7. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK
Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
[TBL] [Abstract][Full Text] [Related]
11. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels.
Lövqvist A; Humm JL; Sheikh A; Finn RD; Koziorowski J; Ruan S; Pentlow KS; Jungbluth A; Welt S; Lee FT; Brechbiel MW; Larson SM
J Nucl Med; 2001 Aug; 42(8):1281-7. PubMed ID: 11483692
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
14. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
15. Radiolocalization of human small cell lung cancer and antigen-positive normal tissues using monoclonal antibody LS2D617.
Wilson BS; Petrella E; Lowe SR; Lien K; Mackensen DG; Gridley DS; Stickney DR
Cancer Res; 1990 May; 50(10):3124-30. PubMed ID: 2159374
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
Lynch TJ; Lambert JM; Coral F; Shefner J; Wen P; Blattler WA; Collinson AR; Ariniello PD; Braman G; Cook S; Esseltine D; Elias A; Skarin A; Ritz J
J Clin Oncol; 1997 Feb; 15(2):723-34. PubMed ID: 9053498
[TBL] [Abstract][Full Text] [Related]
17. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer.
Chaudhry A; Carrasquillo JA; Avis IL; Shuke N; Reynolds JC; Bartholomew R; Larson SM; Cuttitta F; Johnson BE; Mulshine JL
Clin Cancer Res; 1999 Nov; 5(11):3385-93. PubMed ID: 10589749
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
Smaletz O; Diz MD; do Carmo CC; Sabbaga J; Cunha-Junior GF; Azevedo SJ; Maluf FC; Barrios CH; Costa RL; Fontana AG; Madrigal V; Wainstein AJ; Yeda FP; Alves VA; Moro AM; Blasbalg R; Scott AM; Hoffman EW
Gynecol Oncol; 2015 Aug; 138(2):272-7. PubMed ID: 26026738
[TBL] [Abstract][Full Text] [Related]
19. Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens.
Ramsland PA; Farrugia W; Bradford TM; Mark Hogarth P; Scott AM
J Mol Biol; 2004 Jul; 340(4):809-18. PubMed ID: 15223322
[TBL] [Abstract][Full Text] [Related]
20. Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses.
Liu Z; Panousis C; Smyth FE; Murphy R; Wirth V; Cartwright G; Johns TG; Scott AM
Hybrid Hybridomics; 2003 Aug; 22(4):219-28. PubMed ID: 14511567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
